TY  - JOUR
AU  - Ziemssen, Tjalf
AU  - Bass, Ann D
AU  - Berkovich, Regina
AU  - Comi, Giancarlo
AU  - Eichau, Sara
AU  - Hobart, Jeremy
AU  - Hunter, Samuel F
AU  - LaGanke, Christopher
AU  - Limmroth, Volker
AU  - Pelletier, Daniel
AU  - Pozzilli, Carlo
AU  - Schippling, Sven
AU  - Sousa, Livia
AU  - Traboulsee, Anthony
AU  - Uitdehaag, Bernard M J
AU  - Van Wijmeersch, Bart
AU  - Choudhry, Zia
AU  - Daizadeh, Nadia
AU  - Singer, Barry A
AU  - CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators
PY  - 2020
DO  - 10.1007/s40263-020-00749-x
UR  - http://hdl.handle.net/10668/16000
T2  - CNS drugs
AB  - Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a recommended...
LA  - en
KW  - Adult
KW  - Alemtuzumab
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Immunologic Factors
KW  - Interferon beta-1a
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Treatment Outcome
KW  - Young Adult
TI  - Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
TY  - research article
VL  - 34
ER  -